Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18175863 | 0.76 | KMT2A (0.44) | KMT2ATRIM24TRIM33ALDH1A1 | |
| SCHEMBL3250188 | 0.76 | KMT2A (0.44) | KMT2ATRIM24TRIM33ALDH1A1 | |
| SCHEMBL171589 | 0.76 | KMT2A (0.44) | KMT2AALDH1A1 | |
| SCHEMBL4141702 | 0.75 | — | — | |
| Sulfamide SCHEMBL7595070 | 0.75 | — | — | |
| SCHEMBL11688163 | 0.75 | CA1 (0.69) | CA1CA2KMT2ACA7CA12 | |
| SCHEMBL27861636 | 0.74 | KMT2A (0.42) | KMT2AALDH1A1 | |
| SCHEMBL3310954 | 0.74 | KMT2A (0.42) | KMT2AALDH1A1 | |
| SCHEMBL11811714 | 0.73 | KMT2A (0.69) | CA1CA2KMT2AALDH1A1CA12 | |
| SCHEMBL13327648 | 0.72 | KMT2A (0.41) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9156856-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| CN-104945311-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC | 2015-09-30 | — | — | CN | disclosed |
| CN-102282128-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC | 2015-06-17 | — | — | CN | disclosed |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338466-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| CN-102282128-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2387559-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083442-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| US-7309704-B2 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309704-B2 | Heteroaryl urea neuropeptide Y Y5 receptor antagonists | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1102789-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008046-A1 | MONOCYCLIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTION AND COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA1 1290/4885CA2 2352/4885KMT2A 3558/4885 |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA1 1330/4885CA2 2480/4885KMT2A 3498/4885 |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | CA1 1290/4885CA2 2352/4885KMT2A 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.